Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Instil Bio, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
TIL
Nasdaq
2830
instilbio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Instil Bio, Inc.
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
- Jan 14th, 2025 12:00 pm
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
- Nov 15th, 2024 7:38 pm
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Nov 13th, 2024 12:00 pm
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
- Sep 25th, 2024 8:56 am
Here's Why Everyone's Talking About Summit Therapeutics
- Sep 17th, 2024 8:24 am
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
- Sep 16th, 2024 3:23 pm
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
- Sep 16th, 2024 10:00 am
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
- Sep 14th, 2024 8:56 am
Private equity firms are Instil Bio, Inc.'s (NASDAQ:TIL) biggest owners and were rewarded after market cap rose by US$52m last week
- Sep 10th, 2024 5:08 pm
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Aug 13th, 2024 9:00 pm
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
- Aug 1st, 2024 10:00 am
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
- May 10th, 2024 11:00 am
What Makes Instil Bio (TIL) a New Buy Stock
- Mar 27th, 2024 4:00 pm
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Mar 21st, 2024 9:00 pm
Scroll